Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells $906,865.25 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director George Poste sold 33,725 shares of Exelixis stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $26.89, for a total value of $906,865.25. Following the sale, the director now directly owns 199,020 shares of the company’s stock, valued at approximately $5,351,647.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

George Poste also recently made the following trade(s):

• On Tuesday, May 21st, George Poste sold 11,686 shares of Exelixis stock. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56.

Exelixis Stock Performance

NASDAQ:EXEL opened at $26.30 on Thursday. The stock has a market capitalization of $7.97 billion, a PE ratio of 41.09, a P/E/G ratio of 0.60 and a beta of 0.54. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $27.53. The company has a fifty day moving average of $22.98 and a two-hundred day moving average of $22.41.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of EXEL. Fisher Asset Management LLC boosted its holdings in Exelixis by 232.6% in the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after buying an additional 728 shares during the last quarter. GAMMA Investing LLC acquired a new position in Exelixis in the 4th quarter valued at $27,000. Rise Advisors LLC purchased a new position in Exelixis in the 1st quarter valued at $28,000. Park Place Capital Corp acquired a new stake in Exelixis during the 2nd quarter worth $45,000. Finally, USA Financial Formulas boosted its stake in Exelixis by 1,548.0% during the 4th quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,935 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the subject of several recent research reports. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. TD Cowen boosted their price objective on Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. JMP Securities boosted their price target on Exelixis from $27.00 to $29.00 and gave the company a “market outperform” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Exelixis in a research note on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.43.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.